| Status | In progress |
| Process | STA 2018 |
| ID number | 3795 |
Provisional Schedule
| Committee meeting: 1 | 01 June 2022 |
| Expected publication | 10 August 2022 |
Project Team
| Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
| Evidence Review Group / Assessment Group | Kleijnen Systematic Reviews Ltd |
Consultees
| Companies sponsors | Incyte Corporation (tafasitamab) |
| Others | Department of Health and Social Care |
| NHS England | |
| NHS Great Yarmouth & Waveney CCG | |
| NHS Islington CCG | |
| Welsh Government | |
| Patient carer groups | African Caribbean Leukaemia Trust |
| Anthony Nolan | |
| Black Health Agency for Equality | |
| Blood Cancer UK | |
| Cancer Black Care | |
| Cancer Equality | |
| Cancer52 | |
| DKMS | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patients Voice | |
| Leukaemia Cancer Society | |
| Leukaemia Care | |
| Lymphoma Action | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tenovus Cancer Care | |
| WMUK | |
| Professional groups | Association of Cancer Physicians |
| British Committee for Standards in Haematology | |
| British Geriatrics Society | |
| British Institute of Radiology | |
| British Psychosocial Oncology Society | |
| British Society for Haematology | |
| British Society of Interventional Radiology | |
| Cancer Research UK | |
| Health Lumen | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal college of Radiologists | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Clinical Pharmacy Association | |
| UK Oncology Nursing Society | |
| United Kingdom Cutaneous Lymphoma Group |
Commentators
| Associated guideline groups | National Clinical Guideline Centre |
| Associated public health groups | Public Health Wales |
| UK Health Security Agency | |
| Comparator companies | Accord Healthcare (bendamustine, bleomycin, etoposide, gemcitabine, mitoxantrone, oxaliplatin, prednisolone) |
| Advanz Pharma (dexamethasone, prednisolone) | |
| Allergan (dexamethasone, prednisolone) | |
| Aspen (chlorambucil, dexamethasone) | |
| Aspire Pharma (dexamethasone) | |
| Bausch & Lomb (dexamethasone, prednisolone) | |
| Baxter Healthcare (cyclophosphamide, mitoxantrone) | |
| Celgene, a BMS company (lenalidomide) | |
| Cheplapharm Arzneimittel GmbH (etoposide) | |
| Consilient Health (dexamethasone) | |
| Dr Reddy’s Laboratories UK (bendamustine) | |
| Ethypharm (dexamethasone) | |
| Glenmark Pharmaceuticals Europe (dexamethasone) | |
| Hameln Pharma (dexamethasone) | |
| Hospira UK (gemcitabine, mitoxantrone, oxaliplatin, vincristine) | |
| Karo Pharma (prednisolone) | |
| Kent Pharmaceuticals (dexamethasone) | |
| Kyowa Kirin (bleomycin) | |
| Logixx Pharma (prednisolone) | |
| Medac GmBH (etoposide, lomustine, oxaliplatin) | |
| Napp Pharmaceuticals (rituximab) | |
| Novartis (dexamethasone) | |
| Panpharma UK (dexamethasone) | |
| Pfizer (rituximab) | |
| Phoenix Labs (prednisolone) | |
| Ranbaxy (gemcitabine, oxaliplatin) | |
| Rayner Pharmaceuticals (dexamethasone) | |
| Roche Products (polatuzumab, rituximab) | |
| Rosemont (dexamethasone) | |
| RPH Pharmaceuticals (prednisolone) | |
| Sandoz (cyclophosphamide, rituximab) | |
| Sanofi (dexamethasone) | |
| Seacross pharmaceuticals (bendamustine, oxaliplatin) | |
| Servier Laboratories (pixantrone) | |
| Synchrony (dexamethasone) | |
| Teva UK (dexamethasone) | |
| Thame Laboratories (dexamethasone) | |
| Wockhardt UK (dexamethasone, prednisolone) | |
| Zentiva (bendamustine, prednisolone) | |
| General commentators | All Wales Therapeutics & Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Cochrane Haematological Malignancies Group |
| Genomics England | |
| Institute of Cancer Research | |
| Leukaemia Busters | |
| Leukaemia UK | |
| Lymphoma Research Trust | |
| MRC Clinical Trials Unit | |
| National Cancer Research Institute | |
| National Cancer Research Network | |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 September 2021 | Invitation to participate |
| 05 January 2021 | The Department for Health and Social Care has asked NICE to conduct an appraisal of tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-September 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission. |
| 26 August 2020 - 24 September 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 05 December 2017 | In progress. DHSC referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance